Skip to main content

VivoSim Labs, Inc.

corporate_fare Company Profile

VivoSim Labs, Inc.

VIVS·NASDAQ·Life Sciences·CIK 0001497253

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that provides testing of drugs and drug candidates using three-dimensional (3D) human tissue models of liver and intestine. The company offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. VivoSim Labs, Inc. also expects to offer customized services in investigational toxicology, elucidation of drug mechanisms, and other applications of these complex human tissue models. Prior to March 2025, VivoSim Labs, Inc. was a clinical stage biotechnology company focused on developing FXR314 for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease. This focus was based on clinical promise demonstrated in 3D human tissues and strong preclinical data. The company had planned to initiate a Phase 2a clinical trial in UC in the calendar year 2025 and was exploring combination therapies using FXR314 with approved mechanisms in preclinical animal studies and IBD disease models. In March 2025, VivoSim Labs, Inc. sold its FXR program for $10.0 million, with $9.0 million paid at closing and $1.0 million held in escrow for 15 months. The sale also included future milestones of up to $50.0 million in aggregate, contingent on the lead asset, FXR314, achieving key development, regulatory, and commercial milestones. In July 2026, the company received a milestone payment of $5.0 million upon the achievement of a specific development milestone related to FXR314. Effective April 24, 2025, the company changed its corporate name to VivoSim Labs, Inc.

VivoSim Labs, Inc. (NASDAQ:VIVS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for VIVS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • VivoSim Prices Up to $4M Public Offering, Securing Initial $3M Funding
  • VivoSim Labs Amends S-1 for Critical $4M Offering with Highly Dilutive Warrants Amidst Going Concern Warning
  • VivoSim Labs Files S-1 for Public Offering with Warrants, Priced at Premium Amidst Going Concern Warning
  • VivoSim Labs Reports Substantial Doubt About Going Concern Amidst Significant Cash Burn and Nasdaq Delisting Risk

Financial Snapshot

Fiscal year ended March 31, 2026
Revenue
$131K
Net Income
-$13.84M
Diluted EPS
-$5.35
Op. Cash Flow
-$10.83M
Free Cash Flow
-$10.83M
Gross Profit
$131K
Operating Income
-$11.49M
Cash & Equivalents
$5.02M
Debt / Equity
0.00×
Net Margin
-105.67×
Shares Outstanding
2.89M sh
Source: 10-K · filed 2026-07-14 · accession 0001193125-26-303316
$0.2428 -6.90% today
52-week range · as of 2026-11-12 $0.124 – $3.4
Market cap
$5.29M
Volume
149.2M (4.5× avg)
3-mo avg 33.2M
Live data · 2026-11-22 12:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VIVS - Filings & News (Page 2)

VIVS
Apr 01, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.04
Real-time Price: $0.242811 info
Change: -$0.797189 (-77%) info
Market Cap: $5.289M info
VIVS
Mar 31, 2026, 10:17 AM EDT
Filing Type: S-1/A
Importance Score:
9
Price at Filing: $1.42
Real-time Price: $0.242811 info
Change: -$1.17 (-83%) info
Market Cap: $5.289M info
VIVS
Mar 27, 2026, 5:26 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $1.44
Real-time Price: $0.242811 info
Change: -$1.20 (-83%) info
Market Cap: $5.289M info
VIVS
Feb 11, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.92
Real-time Price: $0.242811 info
Change: -$1.68 (-87%) info
Market Cap: $5.289M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets